Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics (SLXN) filed an 8-K announcing a 1-for-15 reverse share split effective after the 28-Jul-25 close. Authorized capital stays US$20,000 but is now divided into 1,481,482 ordinary shares; par value rises to US$0.0135. All issued and outstanding shares are reduced proportionally and will begin trading on a split-adjusted basis under the same ticker at the 29-Jul-25 open. The new ordinary-share CUSIP is G1281K 130.
The company simultaneously delivered a Warrant Adjustment Notice. Each pre-split warrant is now exercisable for 1/15th of a share, and the exercise price is lifted 15× to US$1,552.50 per post-split share. Fractional entitlements will be rounded up at the broker (DTC participant) level. Warrant CUSIP (G1281K 114) and ticker (SLXNW) are unchanged.
The split was approved at the 14-Jul-25 AGM and effected through an amendment to the Amended & Restated Memorandum of Association, filed 28-Jul-25. Items 3.03 and 5.03 detail the warrant modifications and charter amendment, while Item 8.01 incorporates these events by reference.
Silexion Therapeutics Corp (SLXN) will hold an extraordinary general meeting in Aug-2025 to vote on a single item: increasing authorised share capital to US$121,500 divided into 9,000,000 ordinary shares (par US$0.0135) from the post-reverse-split level of 1,481,482 shares.
The board says the extra 7.5 m shares are essential to (1) regain and thereafter maintain compliance with Nasdaq Listing Rule 5550(b)(1) – minimum US$2.5 m shareholders’ equity by 19-Sep-2025 – following a favourable Nasdaq hearings-panel decision on 7-Jul-2025, and (2) fund pre-clinical/clinical RNAi programs and potential business-development deals. Current capacity is only 529,302 unissued shares, viewed as inadequate for equity raises, warrant/option exercises, conversion of a US$3.433 m sponsor note and employee incentives.
The proposed authorisation represents a 507% increase in total authorised shares. The board unanimously recommends voting FOR. Failure would likely trigger Nasdaq delisting. Risks highlighted include substantial dilution, potential share-price pressure and anti-takeover uses of the new shares.
On July 16 2025 Silexion Therapeutics Corp ("SLXN") filed an 8-K announcing a 1-for-15 reverse share split affecting all issued, outstanding and authorized ordinary shares. The split will be effected automatically after market close on 28 Jul 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq at the open on 29 Jul 2025; the ticker remains "SLXN".
- Every 15 existing shares convert into 1 new share.
- Par value increases from $0.0009 to $0.0135 per share.
- No fractional shares will be issued; DTC positions will be rounded up to the nearest whole share.
The Board’s goal is to raise the per-share price to maintain compliance with Nasdaq Capital Market listing standards. Warrants ("SLXNW") are expected to be adjusted pursuant to their terms. Additional details are provided in the press release attached as Exhibit 99.1.
Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K on 9 July 2025 under Item 7.01 (Regulation FD). The sole purpose of the filing is to furnish — not file — a press release (Exhibit 99.1) titled “Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.” No additional financial statements or transaction details are included, and the company explicitly states the information is not incorporated by reference into other Securities Act filings.
Key points
- The press release reports positive preclinical efficacy for SIL204 in human lung cancer cell lines.
- The disclosure is furnished under Regulation FD, ensuring simultaneous public access to the information.
- No revenue, cost, guidance, or clinical-stage data accompany the announcement.
- Exhibits attached: 99.1 (press release) and 104 (Inline XBRL cover data).
Investors receive confirmation of encouraging scientific data but must consult Exhibit 99.1 for experimental specifics, as the 8-K itself contains minimal detail.
Silexion Therapeutics Corp (NASDAQ: SLXN) announced that a Nasdaq hearings panel has granted the company continued listing status, but with conditions. Effective July 8, 2025, the company’s ordinary shares and warrants will move from the Nasdaq Global Market to the Nasdaq Capital Market, keeping their current tickers “SLXN” and “SLXNW.”
The panel’s decision hinges on Silexion’s ability to achieve and maintain at least $2.5 million in shareholders’ equity by September 19, 2025 and to demonstrate that level in an SEC filing that includes a balance sheet dated within 60 days of submission. Nasdaq will retain jurisdiction over the company’s listing status until November 18, 2025; any further rule breaches before that date must be accompanied by an additional compliance plan for panel review.
Silexion also disclosed a potential bid-price deficiency (closing price below $1.00 for 30 consecutive trading days). Management intends to remedy this by executing a 1-for-15 reverse share split shortly after its reconvened annual general meeting on July 14, 2025, pending shareholder approval, with the split expected to take effect on or about July 25, 2025.
Key investor takeaway: Listing is preserved, but the company must raise equity or otherwise strengthen its balance sheet, complete the reverse split, and avoid additional rule breaches. Failure to meet these milestones could trigger delisting despite the current reprieve.
FAQ
What is the current stock price of Silexion Therapeutics (SLXN)?
What is the market cap of Silexion Therapeutics (SLXN)?
